The FDA granted fast track status to VectorY’s VTx-002, an antibody gene therapy targeting TDP-43 protein aggregates in ALS.
MindWalk Holdings Corp. ("MindWalk" or the "Company") (Nasdaq: HYFT) today announced the discovery and validation of ...
Dewpoint Therapeutics, a US biotech developing condensate-modulating therapeutics, has announced the selection of a ...
BOSTON--(BUSINESS WIRE)--SOLA Biosciences, a pioneer in innovative chaperone technology, will present its encouraging preclinical proof-of-concept data for SOL-257, a targeted gene therapy for ...
The pathological accumulation of TDP-43 that underlies many cases of FTD, ALS, and LATE-NC has been notoriously difficult to recapitulate in mice or cultured human cells. In a paper published February ...
In amyotrophic lateral sclerosis and many cases of frontotemporal dementia, the RNA-binding protein TDP-43 abandons the nucleus and clumps up in cytoplasm, disrupting the normal workings of neurons ...
First-in-class condensate-modulating small molecule Development Candidate targeting pathogenic TDP-43 condensates.Restores global TDP-43 splicing ...
In Nature Neuroscience, UConn School of Medicine researchers have revealed a new scientific clue that could unlock the key ...
TDP-43 can be useful biomarker for identifying neuropathological subtypes of frontotemporal dementia
Frontotemporal dementia (FTD) is one of the most common causes of progressive dementia in working-age people. However, making a diagnosis and a prognosis is often challenging because the ...
Accumulation of a protein called TDP-43 is a key feature of ALS and frontotemporal dementia. In a newly published study, researchers report 'seeding' this accumulation through fragments of the culprit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback